Physician profile
Ryan Kennedy
NPI 1295053759
$35,070.60
in general payments reported to CMS, 2019-2025
42 companies · $1,803 in 2025
The $1,803 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,626 · 2020: $4,836 · 2021: $13K · 2022: $8,752 · 2023: $1,585 · 2024: $3,111 · 2025: $1,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,998 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,998.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,511.35 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $6,921.01 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $6,354.28 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Eli Lilly and Company | $1,982.24 | 2020 | |
| Medtronic Minimed, INC. | $1,896.53 | 2019-2020 | |
| Novo Nordisk INC | $1,314.82 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $621.65 | 2019-2024 | |
| Dexcom, INC. | $612.59 | 2019-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $567.19 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $515.40 | 2019-2022 | |
| Amgen INC. | $496.71 | 2019-2025 | Evenity, Tepezza, Repatha |
| Corcept Therapeutics | $387.46 | 2019-2025 | Korlym |
| Abbott Laboratories | $354.72 | 2019-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $285.37 | 2020-2025 | Tymlos |
| Insulet Corporation | $236.82 | 2019-2025 | Omnipod |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $209.12 | 2020-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $205.21 | 2021-2025 | |
| Esperion Therapeutics, INC. | $161.52 | 2020-2024 | Nexletol |
| Tandem Diabetes Care, INC. | $152.41 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $134.03 | 2019-2021 | |
| Abbvie INC. | $120.59 | 2019-2025 | |
| Pfizer INC. | $115.37 | 2020-2024 | |
| Clarus Therapeutics INC. | $110.70 | 2021 | |
| Beta Bionics, INC. | $94.58 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $80.34 | 2023-2025 | Yorvipath |
| Horizon Therapeutics Plc | $76.58 | 2020-2023 | Tepezza |
| Sequel Med Tech, LLC | $68.72 | 2025 | Twiist |
| Kyowa Kirin, INC. | $61.48 | 2023-2025 | Crysvita |
| Averitas Pharma INC. | $49.76 | 2024-2025 | Qutenza |
| Shire North American Group INC | $44.36 | 2019 | |
| Ibsa Pharma INC. | $43.73 | 2020-2024 | Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $43.34 | 2020 | |
| Janssen Pharmaceuticals, INC | $41.36 | 2019 | |
| Cequr Corporation | $30.07 | 2025 | Cequr Simplicity |
| Lifescan, INC. | $28.18 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $26.29 | 2022 | |
| Zealand Pharma US, INC. | $24.38 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.22 | 2020 | |
| Neurocrine Biosciences, INC. | $20.44 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.09 | 2024 | Strensiq |
| Antares Pharma, INC. | $13.86 | 2024 | Xyosted |
| Recordati_rare_diseases_inc. | $13.73 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.